NCT05844787View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

February 23, 2023

Study Completion Date

February 23, 2023

Conditions
Parkinson's Disease
Interventions
DRUG

MT101-5

Tablet

Trial Locations (1)

07094

Frontage Clinical Services, 1nc., Secaucus

Sponsors

Collaborators (1)

Amarex Clinical Research
All Listed Sponsors
collaborator

Amarex Clinical Research

OTHER

lead

Mthera Pharma Co., Ltd.

INDUSTRY

NCT05844787 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers | Biotech Hunter | Biotech Hunter